Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

Item

http://www.wikidata.org/entity/Q37046781

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 February 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

@en

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.

@nl

type

Item

label

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

@en

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.

@nl

prefLabel

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

@en

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.

@nl

P1476

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

@en

P2093

Christine Hicking

http://www.w3.org/2001/XMLSchema#string

Elisabeth Rushing

http://www.w3.org/2001/XMLSchema#string

Henning Leske

http://www.w3.org/2001/XMLSchema#string

Holger Moch

http://www.w3.org/2001/XMLSchema#string

James Perry

http://www.w3.org/2001/XMLSchema#string

Josef Straub

http://www.w3.org/2001/XMLSchema#string

Martin Picard

http://www.w3.org/2001/XMLSchema#string

Michael Weller

http://www.w3.org/2001/XMLSchema#string

Patrick Roth

http://www.w3.org/2001/XMLSchema#string

Roger Stupp

http://www.w3.org/2001/XMLSchema#string

P2860

Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by β8 integrin

N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

αvβ8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion.

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.

P304

15018-15032

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.7588

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26918452

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

4924768

http://www.w3.org/2001/XMLSchema#string